ProKidney director Brian Pereira sells $1.07 million in shares By Investing.com

Brian JG Pereira, a director at ProKidney Corp. (), sold a total of 757,164 shares of Class A Common Stock across multiple transactions between August 18 and August 20, 2026. The sales amounted to approximately $1,067,773, with prices ranging from $1.3712 to $1.4407 per share. The stock currently trades at $1.42, near its 52-week low of $1.30 and down significantly from its 52-week high of $3.48. According to InvestingPro analysis, the company appears overvalued at current levels. InvestingPro Tips highlight that the company is quickly burning through cash and that stock price movements are quite volatile—two of 11 exclusive tips available to subscribers.

On August 18, Mr. Pereira disposed of 257,164 shares, including 229,338 shares held indirectly by the Brian J. G. Pereira 2012 Irrevocable Trust and 27,826 shares held directly. The weighted average selling price for these transactions was $1.3712 per share, with individual sales occurring between $1.345 and $1.40.

The following day, August 19, Mr. Pereira sold an additional 250,000 shares. This included 222,949 shares from the indirect trust holding and 27,051 shares held directly. The weighted average price for these sales was $1.4407 per share, with transactions ranging from $1.38 to $1.50.

The final reported transactions took place on August 20, where Mr. Pereira sold the remaining 250,000 shares. These consisted of 222,948 shares held indirectly by the trust and 27,052 shares held directly. The weighted average selling price for these shares was $1.4199, with individual transactions ranging from $1.38 to $1.47.

Following these reported transactions, Mr. Pereira’s direct and indirect beneficial ownership of ProKidney Class A Common Stock stands at zero.

In other recent news, ProKidney Corp. has announced the appointment of Kenneth Locke as Chief Technical Officer. This development was detailed in a press release from the company. Locke brings experience from his previous role at Carisma Therapeutics, where he managed CMC, Quality, and Regulatory functions. His expertise also includes leading technical strategy for CAR Myeloid programs. At ProKidney, Locke is expected to support clinical development and oversee technology transfer processes related to cell and viral vector manufacturing. This appointment is part of ProKidney’s ongoing efforts to strengthen its leadership team. The company has not disclosed any earnings or revenue results, mergers, or analyst upgrades or downgrades in recent reports.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.